WO2006035293A1 - Formes polymorphiques d'hemifumarate de quetiapine - Google Patents

Formes polymorphiques d'hemifumarate de quetiapine Download PDF

Info

Publication number
WO2006035293A1
WO2006035293A1 PCT/IB2005/002860 IB2005002860W WO2006035293A1 WO 2006035293 A1 WO2006035293 A1 WO 2006035293A1 IB 2005002860 W IB2005002860 W IB 2005002860W WO 2006035293 A1 WO2006035293 A1 WO 2006035293A1
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine hemifumarate
hemifumarate
quetiapine
values
xrd pattern
Prior art date
Application number
PCT/IB2005/002860
Other languages
English (en)
Inventor
Bhargav Pandya
Ram Chander Aryan
Yatendra Kumar
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2006035293A1 publication Critical patent/WO2006035293A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the present invention relates to polymorphic forms of quetiapine hemifumarate, processes for their preparation and pharmaceutical compositions thereof.
  • quetiapine 2-[2-(4-dibenzo[Z?/J[l ,4]thiazepin-l l-ylpiperazin-l-yl)ethoxy]ethanol, commonly known as quetiapine (Formula I), is an antipsychotic drug belonging to the class of dibenzothiazepine derivatives. Quetiapine is commercially available in the form of its hemifumarate salt (2:1). Quetiapine hemifumarate is indicated for the management of the manifestations of psychotic disorders.
  • U.S. Patent No. 4,879,288 discloses a process for the preparation of quetiapine hemifumarate.
  • U.S. Patent No. 6,372,734 discloses a process for the purification of quetiapine which yields crystalline quetiapine.
  • WO 03/80065 provides crystalline forms of quetiapine hemifumarate referred to as Form II and Form III that are solvated polymorphic forms with dichloromethane and chloroform. Summary of the Invention
  • Form IV of quetiapine hemifumarate in one general aspect there is provided Form IV of quetiapine hemifumarate.
  • the Form IV polymorph of quetiapine hemifumarate includes a XRD pattern that includes 2 ⁇ values of 16.96, 22.96, and 23.77.
  • Embodiments of the present invention may include one or more of the following features.
  • the Form IV of of quetiapine hemifumarate may include 2 ⁇ values of 20.80, 21.50, and 24.08 or it may include 2 ⁇ values of 8.98, 12.58, 15.62, 19.62, and 21.92.
  • the Form IV of quetiapine hemifumarate may also include 2 ⁇ values of 8.98, 11.56, 11.90, 12.58, 13.92, 14.02, 14.32, 14.58, 15.04, 15.62, 15.84, 18.08, 18.40, 18.82, 19.62, 20.22, 20.80, 21.50, 21.92, 24.08, 25.48, 25.88, 26.80, 27.80, 28.00, 28.78, 29.26 and 30.30.
  • Form V of quetiapine hemifumarate in another general aspect there is provided Form V of quetiapine hemifumarate.
  • the Form V polymorph of quentiapine hemifumarate includes an XRD pattern that includes 2 ⁇ values at 16.80, 19.36, 22.72, and 23.16.
  • Embodiments of the present invention include one or more of the following features.
  • the Form V of quentiapine hemifumarate may include 2 ⁇ values at 11.64, 19.28, 19.58, and 23.46 or 2 ⁇ values at 7.52, 8.74, 1 1.64, 13.32, 14.26, 14.44, 14.92, 15.32, 15.72, 16.30, 17.54, 17.82, 18.38, 19.28, 19.58, 19.96, 20.20, 20.64, 20.94, 21.74, 22.32, 23.46, 23.84, 24.44, 25.18, 25.32, 26.32, 26.58, 26.64, 27.08, 27.96, 28.74, 29.06, 29.40, 29.94, 30.46, 30.82, 31.40, 31.76, 31.86, 32.10, 32.44, 33.00, 33.38, 34.04, 34.50, 35.10, 35.38, 36.12, 36.62, 37.50, 37.84, 38.30, 39.18 and 39.64.
  • a process for the preparation of Form IV of quetiapine hemifumarate includes heating quetiapine hemifumarate with chloroform to form a reaction mass, cooling the reaction mass and isolating Form IV of quetiapine hemifumarate, wherein the Form IV of quetiapine hemifumarate has a XRD pattern includes 2 ⁇ values of 16.96, 22.96, and 23.77.
  • a process for preparation of Form V of quetiapine hemifumarate includes stirring quetiapine hemifumarate in tetrahydrofuran to form a mixture, and isolating Form V of quetiapine hemifumarate from the mixture, wherein the Form V of quetiapine hemifumarate has an XRD pattern includes 2 ⁇ values at 16.80, 19.36, 22.72, and 23.16.
  • a pharmaceutical composition includes one or both of Form IV or Form V of quetiapine hemifumarate and one or more pharmaceutically acceptable excipients.
  • a method for the management of the manifestations of psychotic disorders includes administering to a mammal in need thereof a pharmaceutical composition that includes one or both of Form IV or Form V of quetiapine hemifumarate and one or more pharmaceutically acceptable excipients.
  • Figure 1 depicts an X-ray diffractogram of Form IV of quetiapine hemifumarate.
  • Figure 2 depicts a FTIR spectrum of Form IV of quetiapine hemifumarate
  • Figure 3 depicts an X-ray diffractogram of Form V of quetiapine hemifumarate.
  • Figure 4 depict FTIR spectrum of Form V of quetiapine hemifumarate.
  • Form IV and V polymorphic forms of quetiapine hemifumarate, hereinafter referred to as Form IV and V, which are characteristically different from the earlier knowns Form I, II and III.
  • the present invention provides for a polymorph of quetiapine hemifumarate, Form IV, having a X-Ray Powder Diffraction (XRD) pattern as depicted in Figure 1.
  • Form IV includes characteristic 2 ⁇ values at 8.98, 1 1.56, 1 1.90, 12.58, 13.92, 14.02, 14.32, 14.58, 15.04, 15.62, 15.84, 16.96, 18.08, 18.40, 18.82, 19.62, 20.22, 20.80, 21.50, 21.92, 22.96, 23.70, 24.08, 25.48, 25.88, 26.80, 27.80, 28.00, 28.78, 29.26 and 30.30.
  • Form IV of quetiapine hemifumarate is a chloroform solvate of quetiapine hemifumarate.
  • FTIR Fourier Transform Infrared
  • Form V includes characteristic 2 ⁇ values at 7.52, 8.74, 1 1.64, 13.32, 14.26, 14.44, 14.92, 15.32, 15.72, 16.30, 16.80, 17.54, 17.82, 18.38, 19.28, 19.36, 19.58, 19.96, 20.20, 20.64, 20.94, 21.74, 22.32, 22.72, 23.16, 23.46, 23.84, 24.44, 25.18, 25.32, 26.32, 26.58, 26.64, 27.08, 27.96, 28.74, 29.06, 29.40, 29.94, 30.46, 30.82, 31.40, 31.76, 31.86, 32.10, 32.44, 33.00, 33.38, 34.04, 34.50, 35.10, 35.38, 36.12, 36.62, 37.50, 37.84, 38.30, 39
  • Form V of quetiapine hemifumarate is a tetrahydrofuran solvate of quetiapine hemifumarate.
  • the Fourier Transform Infrared (FTIR) spectrum of Form V of quetiapine hemifumarate in potassium bromide is depicted in Figure 4.
  • Also provided in the present invention is a process for preparation of Form IV of quetiapine hemifumarate. The process includes heating quetiapine hemifumarate with chloroform to form a reaction mass, cooling the reaction mass and isolating Form IV of quetiapine hemifumarate.
  • the quetiapine hemifumarate may be prepared by any processes reported in the art.
  • the quetiapine hemifurate is heated in chloroform and the resultant reaction mass is slowly cooled.
  • the reaction mass is separated, filtered and dried under vacuum at ambient temperature for 3 hours to get Form IV of quetiapine hemifumarate.
  • the process includes stirring quetiapine hemifumarate in tetrahydrofuran and isolating Form V of quetiapine hemifumarate from the mixture.
  • Quetiapine hemifumarate is stirred with tetrahydrofuran at ambient temperature for 3 hours to 80 hours and the resultant mass is filtered and dried under vacuum to get Form V of quetiapine hemifumarate.
  • compositions which include Form IV and/or Form V of quetiapine hemifumarate.
  • the pharmaceutical compositions may include one or more pharmaceutically acceptable excipients.
  • the present invention also provides a method for the management of the manifestations of psychotic disorders.
  • the method includes administering to a mammal in need thereof a therapeutically effective amount of Form IV and/or Form V of quetiapine hemifumarate.
  • Example 1 Preparation of Form IV of Quetiapine Hemifumarate
  • Quetiapine hemifumarate (2 gm) was heated with chloroform (10 ml) for 30 minutes at reflux temperature. The resultant mass was cooled to an ambient temperature and stirred for between 28 to 30 hours. The separated product was filtered and washed with chilled chloroform. The resulting cake was dried in a vacuum oven at about 25 0 C to 3O 0 C for between 4 to 16 hours to get Form IV of quetiapine hemifumarate. Yield: 1.6 gm.
  • Example 2 Preparation of Form V of Quetiapine Hemifumarate Quetiapine hemifumarate Form IV (1 gm) was mixed in to tetrahydrofuran (10 ml).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles formes polymorphiques d'hémifumarate de quétiapine, un procédé de préparation de celles-ci ainsi que des compositions pharmaceutiques les contenant.
PCT/IB2005/002860 2004-09-27 2005-09-27 Formes polymorphiques d'hemifumarate de quetiapine WO2006035293A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1852DE2004 2004-09-27
IN1852/DEL/2004 2004-09-27

Publications (1)

Publication Number Publication Date
WO2006035293A1 true WO2006035293A1 (fr) 2006-04-06

Family

ID=35462402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002860 WO2006035293A1 (fr) 2004-09-27 2005-09-27 Formes polymorphiques d'hemifumarate de quetiapine

Country Status (1)

Country Link
WO (1) WO2006035293A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2010100623A1 (fr) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Procede de preparation de fumarate de quetiapine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879288A (en) * 1986-03-27 1989-11-07 Ici Americas Inc. Novel dibenzothiazepine antipsychotic
WO2001055125A1 (fr) * 2000-01-25 2001-08-02 EGIS Gyógyszergyár Rt. Procédé de préparation de quétiapine et des ses intermédiaires
US6372734B1 (en) * 1997-08-01 2002-04-16 Zeneca Limited Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
WO2003080065A1 (fr) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Formes cristallines d'hemifumarate de quetiapine
WO2004078735A1 (fr) * 2003-03-03 2004-09-16 Hetero Drugs Limited Nouveaux polymorphes du fumarate de quetiapine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879288A (en) * 1986-03-27 1989-11-07 Ici Americas Inc. Novel dibenzothiazepine antipsychotic
US6372734B1 (en) * 1997-08-01 2002-04-16 Zeneca Limited Crystalline dibenzothiazepine derivative and its use as an antipsychotic agent
WO2001055125A1 (fr) * 2000-01-25 2001-08-02 EGIS Gyógyszergyár Rt. Procédé de préparation de quétiapine et des ses intermédiaires
WO2003080065A1 (fr) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Formes cristallines d'hemifumarate de quetiapine
WO2004078735A1 (fr) * 2003-03-03 2004-09-16 Hetero Drugs Limited Nouveaux polymorphes du fumarate de quetiapine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAIRA, M. R.: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: "Guidance for Industry: Q3C - Tables and List, Revision 1", November 2003, FOOD AND DRUG ADMINISTRATION, ROCKVILLE, MD, USA, XP002360437 *
WARAWA E J ET AL: "Behavioral approach to nondyskinetic dopamine antagonists: Identification of Seroquel", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 1 February 2001 (2001-02-01), pages 372 - 389, XP002213291, ISSN: 0022-2623 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2010100623A1 (fr) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Procede de preparation de fumarate de quetiapine

Similar Documents

Publication Publication Date Title
EP3248983B1 (fr) Forme cristalline a de l'acide obéticholique et son procédé de préparation
CA2419314C (fr) Preparation de risperidone
KR20040012922A (ko) １-＇４-(５-시아노인돌-３-일)부틸-４-(２-카르바모일벤조퓨란-５-일)피페라진 하이드로클로라이드의 다형태
JP2015107976A (ja) 結晶形態のテノホビルジソプロキシル及びその製造方法
WO2007010555A2 (fr) Nouvelles formes cristallines d'hydrochlorure de moxifloxacine et procede de preparation associe
US20090197907A1 (en) Novel crystalline form of rupatadine free base
EP1303517A1 (fr) Indoloquinazolinones
JP2005350459A (ja) フェキソフェナジンの多形体およびその製造方法
MXPA03003459A (es) Base venlafaxina cristalina y polimorfos novedosos de clorhidrato de venlafaxina, procesos para su preparacion.
US7238686B2 (en) Polymorphs of quetiapine fumarate
EP0844997A1 (fr) Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation
WO2006035293A1 (fr) Formes polymorphiques d'hemifumarate de quetiapine
CN107531744B (zh) 一种奥贝胆酸的新结晶形式及其制备方法
JP2005511668A (ja) 結晶性ベンラファキシン塩基及びベンラファキシン塩酸塩の新規多形、並びにそれらの製法
WO2004089948A1 (fr) Nouvelles formes cristallines d'hydrochlorure de ziprasidone
WO2011067356A2 (fr) Polymorphes d'un inhibiteur de mek
WO2002012200A1 (fr) Preparation de risperidone
CA2493370C (fr) Formes cristallines de l'olanzapine et procedes de preparation desdites formes
US20070167494A1 (en) Process for preparing a polymorph or rosiglitazone maleate
EP2053043A1 (fr) Sel cristallin de montelukast
WO2003027106A1 (fr) Procede de preparation de polymorphes ii cristallins de lamivudine
US20040097528A1 (en) Crystalline solid famciclovir forms I, II, III and preparation thereof
WO2012001357A1 (fr) Forme cristalline de la prulifloxacine et procédés pour sa préparation
AU700976B2 (en) Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
AU2006265277A1 (en) Crystalline forms of macrolide compounds endowed with antiinflammatory activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase